Skip to main content

Security report for bial.com

BIAL · Healthcare · Portugal

Medium risk. 3 critical or high findings in GDPR outside view and SSL/TLS.

Security score

65/100

Risk levelMedium

0–100, higher is better. How it is calculated

BIAL is a well-established pharmaceutical company founded in 1924, focused on discovering, developing, and commercializing innovative therapeutic solutions. The company maintains a strong global presence and targets healthcare professionals, researchers, and patients. The website reflects a mature digital presence with comprehensive content, clear navigation, and multi-language support. Technically, the site uses modern frameworks such as Next.js and React, integrates multiple analytics and marketing tools, and follows good performance and accessibility practices. Security posture is strong with HTTPS, security headers, and no visible vulnerabilities, although explicit security policies and incident response contacts are not found. Overall, the website demonstrates high professionalism and trustworthiness, supporting BIAL's market position as a leading pharmaceutical entity.

Scanned

NIS2 and GDPR posture

GDPR outside view
43/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      No HTTPS encryption

      GDPR requires appropriate security measures for personal data

      What to do: Implement SSL/TLS certificate for HTTPS

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      No HTTPS Encryption

      Website does not use HTTPS encryption, making all data transmission vulnerable to interception

      What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS

Need hands-on remediation? Email guard@offseq.com

Keep watching bial.com

This scan found 15 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
80
Email security
80
DNS health
85
Network security
100
GDPR outside view
43
Average
65

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

BIAL operates in the healthcare sector with a focus on pharmaceutical research and development. The business model centers on innovation and commercialization of medicines, supported by clinical trials and scientific research. The company exhibits a large enterprise scale with a global footprint. Its digital ecosystem includes partnerships and marketing integrations, enhancing brand visibility and user engagement. The website content and structure indicate a strategic approach to stakeholder communication, emphasizing transparency and corporate responsibility. Growth indicators include active news updates, career opportunities, and foundation support for research, reinforcing BIAL's commitment to scientific advancement.

Security posture

The website demonstrates a mature security posture with enforced HTTPS, comprehensive security headers, and absence of exposed sensitive data. Tracking and analytics scripts are implemented with privacy considerations, and cookie consent mechanisms are present. However, the lack of a dedicated security policy page and incident response contact information suggests room for improvement in transparency and readiness. No vulnerabilities or suspicious domains were detected. The security score is high, reflecting adherence to best practices, but strategic enhancements in policy disclosure and incident handling would strengthen overall security culture.

Recommendations

  1. Publish a dedicated security policy page outlining security frameworks and practices.
  2. Provide clear incident response contact channels such as security@ or abuse@ emails.
  3. Implement and publicize a vulnerability disclosure program or security.txt file.
  4. Regularly review and update third-party scripts to mitigate potential vulnerabilities.
  5. Enhance contact information with direct phone numbers or emails for security and compliance inquiries.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
BIAL
Description
BIAL is an innovative pharmaceutical company. Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions.
Key services
Pharmaceutical research, Drug development, Clinical trials, Commercialization of medicines
Content quality
excellent
Branding
consistent

Technology

Stack
React, Next.js, Google Tag Manager, Google Analytics, Facebook Pixel, Hotjar, YouTube API, Usabilla
Frameworks
Next.js
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
90/100
Good practices seen
  • HTTPS enforced
  • Use of security headers
  • No exposed sensitive data in HTML
  • Secure forms with no visible vulnerabilities

Analytics and tracking

Services
Google Analytics, Hotjar, LinkedIn Insight Tag, Facebook Pixel
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Facebook Pixel, Hotjar, LinkedIn Insight Tag
Marketing tools
Usabilla
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Content is comprehensive and relevant to pharmaceutical industry.
  3. Multiple language support with locale picker available.
  4. Social media presence is active and linked.
  5. Security best practices are implemented with HTTPS and security headers.
  6. No signs of blocking or WAF challenges detected.
  7. Privacy and cookie policies are present and accessible.
  8. No direct contact emails or phone numbers found on main pages; contact form is primary contact method.
  9. No explicit security policy or incident response information found.
  10. Use of modern web technologies and analytics tools.
Technical notes

Notes

The website is built on a modern tech stack including React and Next.js, leveraging Contentful as CMS. It integrates multiple analytics and marketing tools such as Google Analytics, Hotjar, Facebook Pixel, and LinkedIn Insight Tag. The site is mobile-optimized, accessible, and SEO-friendly with proper meta tags and structured data. Performance is moderate, with potential for optimization in loading times. The use of security headers and HTTPS ensures a secure browsing experience. Technical debt appears low, but continuous monitoring and updates are recommended to maintain security and performance standards.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with bial.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review bial.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.